Background: Although warfarin is potentiated by omeprazole through interference of the cytochrome P450 system, little is known in other proton pump inhibitors (PPIs). We evaluated the interactions between warfarin and lansoprazole / sodium rabeprazole. Methods: This retrospective study consisted of 161 atrial fibrillation (AF) patients who underwent catheter ablation of AF. Optimal anticoagulation treatment by warfarin was performed in all patients without taking PPIs prior to procedure. Following ablation, 15 mg of lansoprazole or 10 mg of sodium rabeprazole was administered in patients presenting Gastrointestinal discomfort. We investigated the dose of warfarin required to maintain optimal prothrombin time international normalized ratio (PT-INR) before the proceudre and at 3 months after administration of PPIs. Results: Lansoprazole and sodium rabeprazole were administered in 62 and 63 patients with gastroesophagitis symptom, respectively. There were no significant differences in dose of warfarin between before and after taking lansoprazole (4.0 1.2 mg/day vs. 4.1 1.2 mg/day, p=NS) / rabeprazole (3.8 1.0 mg/day vs. 3.8 1.1 mg/day, p=NS). Additionally, no differences were observed in the value of PT-INR between before and after taking PPIs in patients with lansoprazole (1.9 0.3 vs. 2.0 0.5, P=NS) and rabeprazole (2.1 0.4 vs. 2.1 0.5, P=NS). Conclusion: Lansoprazole and rabeprazole could be safely used in patients with anticoagulant treatment by warfarin.
